After 50 Years, DEA Reschedules Marijuana: A Milestone In Federal Cannabis Policy

Photo by Ben Stevens

After 50 Years, DEA Reschedules Marijuana: A Milestone In Federal Cannabis Policy

After half a century, this marks a historic milestone.

The Drug Enforcement Administration (DEA) has long held cannabis in its tight grip, designating it as a Schedule I substance alongside heroin and LSD since 1970.

But as of late, the winds of change are sweeping through the halls of federal drug policy.

In a historic move, the DEA has proposed shifting marijuana from its current Schedule I status to Schedule III under the Controlled Substances Act (CSA). This seismic shift, confirmed by the Justice Department on Tuesday, marks a significant departure from decades of staunch prohibition.

While a reclassification falls short of federal legalization, it paves the way for pivotal changes.

Under Schedule III, cannabis retains its status as illegal, albeit with nuanced implications:

  • Cannabis would still be illegal but recognized for medical use, potentially allowing prescriptions by physicians.

  • Cannabis businesses could claim federal tax deductions, currently prohibited under IRS code 280E.

  • There would be greater research opportunities, fostering more extensive exploration and leniency.

  • It could prompt states to legalize cannabis, both medicinally and recreationally.

  • Federal enforcement policies might shift in favor of state-legal cannabis operations.

  • A reevaluation of cannabis’s abuse potential relative to other substances might occur.

This rescheduling reflects a growing acknowledgment of cannabis’s therapeutic potential and might spur further state-level legalization initiatives. Already, 24 states have legalized recreational cannabis, and an additional seven have decriminalized its use as of November 2023.

Extensive scientific research, including a year-long review by the U.S. Department of Health and Human Services (HHS), supports the potential reclassification.

This review involved surveying over 30,000 healthcare professionals across 43 U.S. jurisdictions, resulting in the recommendation for medical cannabis use in over 6 million patients with 15 different medical conditions.

As the rescheduling proposal awaits review by the White House Office of Management and Budget, the head of the Food and Drug Administration (FDA) emphasizes the need for a swift decision, as there’s “no reason” for the delay.

Herb Recommended Products:

Featured Brands:

Herb Recommended Products:

READ MORE

Airo Brands: Top Vaping Reviews
Culture |
03.02.2023
Airo Brands: Top Vaping Reviews
Dr. Dabber SWITCH Review from a True Cannabis Snob
Learn |
23.03.2020
Dr. Dabber SWITCH Review from a True Cannabis Snob
THC Vape Pens For Anxiety
Guides |
31.01.2024
THC Vape Pens For Anxiety
Here Are The Rarest Cannabis Strains On Earth Right Now
Learn |
14.05.2022
Here Are The Rarest Cannabis Strains On Earth Right Now
How To Roll An Infused Joint
Guides |
21.12.2021
How To Roll An Infused Joint
What Is Delta-9P?
Learn |
30.04.2023
What Is Delta-9P?
Cannabis Coffee Cake
recipes |
07.01.2012
Cannabis Coffee Cake
4 Reasons Why Joints Are The Best Way To Smoke Weed
Learn |
13.07.2023
4 Reasons Why Joints Are The Best Way To Smoke Weed
What Is PGR Cannabis?
Learn |
04.03.2024
What Is PGR Cannabis?
The Top Premium Cannabis Strains Of 2024
Guides |
05.03.2024
The Top Premium Cannabis Strains Of 2024